Results 231 to 240 of about 2,361,739 (390)

When AI chatbots understand emotions: exploring the mechanisms of self-disclosure from emotional arousal to psychological acceptance-a hybrid SEM-ANN-NCA analysis across multiple interaction configurations. [PDF]

Front Psychol
Peng X, Qian Y, He Y.
europepmc   +1 more source

Goodwill Impairment Test Disclosures under Uncertainty

, 2016
Karol Marek Klimczak, Marta Dynel, Anna Pikos   +2 more
openalex   +1 more source

Voluntary disclosures in mergers and acquisitions

, 2007
Scott Wandler, Scott Wandler
openalex   +2 more sources

Accounting Information, Disclosure, and the Cost of Capital

, 2007
Richard A. Lambert, C. Leuz, Robert E. Verrecchia   +2 more
semanticscholar   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

The Determinants of Voluntary Disclosure in Emerging Markets: The Case of Egypt

, 2017
Mostafa I. Elfeky, Alireza Nasiri
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Ethical and clinical challenges in managing low-penetrance CNVs: insights from Portuguese clinical geneticists. [PDF]

Front Genet
Soares AR, Da Silva JD, Caldas Afonso A, Carvalho AS.   +3 more
europepmc   +1 more source

Replication data for: Disclosure by Politicians

, 2010
Simeon Djankov, Rafael La Porta, Florencio López‐de‐Silanes, Andrei Shleifer   +3 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source